Amgen’s Sotorasib Updates Raise New Questions For KRAS Program

Lower Dose Being Tested Against Higher Dose Under FDA Review

 
• By Mandy Jackson
Stack of question marks on wood table
Amgen's Lumakras updates raised new questions about the KRAS G12C inhibitor • Source: Alamy

More from Anticancer

More from Therapeutic Category